Publications by authors named "J M Van Dieren"
Article Synopsis
- CDH1 pathogenic variants are linked to hereditary diffuse gastric cancer (HDGC), increasing the risk of developing diffuse gastric cancer (DGC) and lobular breast cancer (LBC), with prophylactic total gastrectomy being the standard prevention method for at-risk individuals.
- Recent research indicates that the lifetime risk of advanced DGC in CDH1 PV carriers is lower than previously thought, estimated at 13-19%, prompting discussions about the appropriateness of uniform recommendations for prophylactic total gastrectomy given the potential consequences.
- There is a growing interest in utilizing alternative strategies like endoscopic surveillance, focusing on identifying deeper infiltrative lesions rather than all small signet ring cell lesions, to improve individual management of CDH1
Background: Since 2016, staging laparoscopy has been implemented in the diagnostic workup of patients with gastric cancer. Staging laparoscopy aims to detect incurable disease (peritoneal metastases and irresectable tumors) and to prevent futile laparotomies.
Methods: In this population-based nationwide study, we sought patient- and tumor characteristics associated with undergoing a staging laparoscopy.
Introduction: Severe immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICIs) can lead to admission to the intensive care unit (ICU). In this retrospective study, we determined the incidence, treatment patterns and survival outcomes of this patient population at a comprehensive cancer center.
Methods: All patients admitted to the ICU due to irAEs from ICI treatment between January 2015 and July 2022 were included.
Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD).
Methods: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer.
Detection of peritoneal dissemination (PD) in gastric cancer (GC) patients remains challenging. The feasibility of tumor-guided cell-free DNA (cfDNA) detection in prospectively collected peritoneal fluid (ascites and peritoneal lavage) was investigated and compared to conventional cytology in 28 patients. Besides conventional cytology, next generation sequencing was performed on primary tumor DNA and cell-free DNA from peritoneal fluid.
View Article and Find Full Text PDF